Exousia Pro Amends Reg A Offering, Finalizes Pricing at $0.03/Share, and Settles Major Litigation

summarizeSummary

Exousia Pro, Inc. filed an amended Regulation A offering, finalizing the price at $0.03 per share for up to 65 million shares, and simultaneously announced a significant litigation settlement that reduces debt and cancels over 6 million shares.

check_boxKey Events

• Amended Regulation A Offering Finalizes Pricing

  This Post-Qualification Offering Circular Amendment No. 4 finalizes the offering price at $0.03 per share for up to 49,916,666 shares offered by the company and 11,329,431 shares offered by selling shareholders. This follows the previous 1-A POS filing on March 11, 2026, which increased the number of shares offered by the company.

• Significant Share Dilution

  The offering, if fully subscribed, would result in the issuance of 61,246,097 new shares, representing a potential dilution of approximately 139% to the current 44,048,470 outstanding shares. The offering price of $0.03 per share is at an approximate 18.9% discount to the current market price of $0.037.

• Favorable Litigation Settlement Detailed

  The company reached a settlement in March 2026 for a lawsuit against a former officer. This settlement requires a $147,500 payment but results in the cancellation of $300,000 in promissory notes and the return of 6,297,511 shares of common stock to treasury, reducing both debt and outstanding shares.

• Going Concern Warning

  The company explicitly states that it has incurred losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern. The proceeds from this offering are intended to fund investigational new drug trials, product development, and working capital, which are critical for its operations.

auto_awesomeAnalysis

Exousia Pro, Inc. filed an amended Regulation A offering, finalizing the offering price at $0.03 per share, a discount of approximately 18.9% to the current market price. This offering is critical for the company, which explicitly states substantial doubt about its ability to continue as a going concern. The company aims to raise up to $1.5 million from its own share sales, with proceeds allocated to R&D, new product development, and working capital. Additionally, selling shareholders are offering up to 11.3 million shares, from which the company will receive no proceeds. If all shares in this offering are sold, it would result in a significant dilution of approximately 139% to existing shareholders.

Simultaneously, the company announced a favorable litigation settlement, which was previously hinted at in a news release on March 16, 2026. This settlement requires a $147,500 payment but results in the cancellation of $300,000 in promissory notes and the return of 6,297,511 shares of common stock to treasury, significantly improving the balance sheet and reducing the outstanding share count. This positive development partially offsets the dilutive impact of the offering. Furthermore, the company has outstanding Series B Convertible Preferred Stock that could convert into an additional 47 million shares upon uplisting to a national exchange, representing substantial future dilution.